Globus Medical Inc. (GMED)
Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.
Globus Medical, Inc. (GMED) Q2 2024 Earnings Call Transcript
Globus Medical, Inc. (NYSE:GMED ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Matthew Miksic - Barclays Vikramjeet Chopra - Wells Fargo Shagun Singh - RBC CM Steve Lichtman - Oppenheimer David Saxon - Needham & Company Matthew O'Brien - Piper Sandler Jason Wittes - ROTH Matthew Blackman - Stifel Ryan Zimmerman - BTIG Ravi Mishra - Truist Craig Bijou - BofA Operator Welcome to Globus Medical's Second Quarter 2024 Earnings Call. At this time, all lines will be on mute and a Q&A session will be held after the prepared remarks.
Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Q2 Earnings and Revenues Beat Estimates
Globus Medical (GMED) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.63 per share a year ago.
Globus Medical (GMED) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Globus Medical (GMED) Global Sales, Innovation Aid Growth
In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.
Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D
Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.
Here's Why Globus Medical (GMED) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical, Inc. (GMED) Hits Fresh High: Is There Still Room to Run?
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
GMED vs. SONVY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?
Here's Why Globus Medical (GMED) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
